Did Penumbra beat or miss consensus estimates last quarter?

What guidance did Penumbra's management provide for the next earnings period?

What factors drove the changes in Penumbra's revenue and profit?

What is the revenue and EPS growth rate for Penumbra year over year?

What were the key takeaways from Penumbra's earnings call?

What is the market's earnings forecast for Penumbra next quarter?

What were the key takeaways from Penumbra’s earnings call?

What is Penumbra's latest dividend and current dividend yield?

- **Revenue Growth**: Q3 2025 revenue up 17.8% YoY to $354.7M, driven by 34% VTE growth and 29.2% embolization/access expansion.
- **CAVT Innovation**: FDA clears Lightning Bolt 16 and Flash 3.0; STORM-PE trial validates CAVT superiority, spurring hospital protocol updates.
- **Margin Expansion**: Gross margin 67.8% (up 130bps YoY); targeting >70% by 2026. Operating income $48.8M (13.8% of revenue).
- **Guidance Update**: 2025 revenue raised to $1.375-$1.380B; U.S. thrombectomy growth 20-21%.
- **Pipeline Momentum**: Thunderbolt FDA review active; Flash 3.0 enhances case efficiency, Ruby XL stabilizes production.

**【CEO Summary Section】**
- Q3 2025 revenue reached $354.7 million, up 17.8% YoY, driven by 18.5% growth in U.S. thrombectomy and 29.2% in embolization/access. VTE franchise grew 34%, while U.S. embolization/access revenue rose 29.2%.
- FDA cleared Lightning Bolt 16 and Flash 3.0, enhancing CAVT portfolio for over 800,000 U.S. VTE patients. STORM-PE trial showed CAVT superior to anticoagulation alone, with faster recovery and safety profile.
- Gross margin expanded 130bps to 67.8%, targeting >70% by end-2026. Raised 2025 revenue guidance to $1.375-$1.380 billion, with U.S. thrombectomy growth of 20-21%.

**【CFO Financial Commentary】**
- Q3 GAAP revenue $354.7M, non-GAAP operating income $48.8M (13.8% of revenue). Gross margin 67.8%, up 180bps QoQ, driven by product and regional mix. Operating expenses $191.6M (54% of revenue), reflecting embolization team build-out.
- Adjusted EBITDA $66.7M (18.8% of revenue). Cash balance $470.3M, up $45.7M QoQ. Full-year guidance maintained for margin expansion.

**【Q&A Highlights】**
- **Thunderbolt Approval**: FDA review ongoing; no timeline provided, but team optimistic. Product launch readiness confirmed post-approval.
- **STORM-PE Impact**: Non-interventionalists updating protocols, accelerating CAVT adoption. Q4 and 2026 growth expected from procedural volume increase.
- **Margins**: Gross margin to expand >70% by 2026; operating expenses stabilize post-sales team build-out.
- **International Recovery**: China headwinds easing; rest-of-world growth 6.6% YoY. Focus on neurovascular innovation (e.g., Thunderbolt) to drive future growth.
- **Product Pipeline**: Lightning Flash 3.0 improves case times; Ruby XL stabilizes production, supporting margin accretion.

Penumbra, Inc. (PEN) Q3 2025 Earnings Call Transcript

- **Revenue Growth**: Q2 2025 revenue of $339.5M (+13.4% YoY), driven by 22.6% U.S. thrombectomy growth and international expansion.
- **Strategic Investments**: Added 90 new sales reps to separate thrombectomy and embolization teams, targeting >70% gross margin by 2026.
- **Clinical Milestones**: Completed enrollment in STORM-PE trial, launched STRIDE II for latest-gen CAVT tech, and advanced Thunderbolt FDA review.
- **Profitability**: Operating income of $40.8M (12% of revenue), adjusted EBITDA of $61.4M (18.1% of revenue), with strong cash position of $424.6M.
- **China Recovery**: Headwinds easing, small order filled but no material contribution. Focus on rebuilding international business with margin-appropriate products.


**【CEO Summary Section】**
- **Revenue Growth**: Q2 2025 total revenue of $339.5M, up 13.4% YoY (12.7% constant currency), driven by U.S. thrombectomy (+22.6%) and international expansion.
- **U.S. Thrombectomy Dominance**: VTE franchise grew 42% YoY, with Flash 2.0 and Bolt 12 driving conversions from anticoagulation and lytics.
- **Gross Margin Management**: 66% gross margin (in-line with expectations), with planned RUBY XL inventory build impacting Q2. Targeting >70% gross margin by end-2026.
- **Sales Force Expansion**: Added 50 embolization reps and 40 vascular clinical specialists to separate thrombectomy and embolization teams, positioning for long-term growth.
- **Clinical Trials**: Completed enrollment in STORM-PE trial (CAVT + anticoagulation vs. anticoagulation alone) and launched STRIDE II for latest-gen CAVT tech in arterial thrombectomy.
- **Neurovascular Momentum**: RED 72 SILVER LABEL adoption strong, Swift coil for MMA embolization gaining traction, and Thunderbolt FDA review ongoing.

**【CFO Financial Commentary】**
- **Revenue Breakdown**: Thrombectomy ($230.3M, +13.1% YoY), embolization/access ($109.2M, +13.9% YoY). U.S. revenue grew 19.5%, offsetting 3.2% decline in China.
- **Gross Margin Dynamics**: 66% vs. 54.4% prior year (including $33.4M one-time write-off). Sequential decline due to XL launch and international mix, but on track for 2025 targets.
- **Operating Expenses**: $183.2M (54% of revenue), up 11% YoY due to commercial team expansion. R&D ($23.2M) and SG&A ($160M) reflect strategic investments.
- **Profitability**: Operating income $40.8M (12% of revenue vs. -$1.6M prior year), adjusted EBITDA $61.4M (18.1% of revenue).
- **Cash Position**: $424.6M in cash, up $45.7M QoQ, supporting positive operating cash flow trends.

**【Q&A Highlights】**
- **STORM-PE Trial**: First randomized trial comparing CAVT + anticoagulation to anticoagulation alone, with enrollment completed ahead of schedule. Potential to shift PE treatment paradigm.
- **Thunderbolt Update**: FDA review ongoing, no timeline provided. Adam reaffirmed enthusiasm for product's long-term impact.
- **Sales Force Impact**: New embolization team expected to drive RUBY XL adoption, with minimal near-term margin impact due to product accretiveness.
- **China Recovery**: Headwinds easing, small order filled but no material contribution. Focus on rebuilding international business with margin-appropriate products.
- **Market Share**: U.S. VTE penetration >50%, continuing share gains in DVT and PE through clinical evidence and product differentiation.


Penumbra, Inc. (PEN) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: Q1 2025 revenue up 16.3% YoY to $324.1 million, driven by 25% U.S. thrombectomy growth and 42% VTE franchise expansion.
- **Margin Expansion**: Gross margin 66.6% (vs. 65% Q1 2024); targeting >70% by end-2026. Operating income $40.4 million (12.4% of revenue).
- **China Adjustment**: Removed $5 million China revenue from 2025 forecast due to macro challenges; U.S. sales now 79.2% of total.
- **Product Momentum**: Lightning Bolt 12 and Bolt 6X/7 outperformed expectations; Ruby XL launch in Q2/Q3 2025 to address peripheral embolization demand.
- **Guidance Update**: 2025 revenue growth 12-14% YoY; U.S. thrombectomy raised to 20-21% YoY. Maintain focus on profitable growth and margin expansion.

**【CEO Summary Section】**
- Q1 2025 total revenue: $324.1 million (+16.3% YoY, +16.9% constant currency). U.S. thrombectomy revenue up 25% YoY to $187.9 million, driven by VTE franchise growth of 42%.
- Gross margin expanded to 66.6% (vs. 65% Q1 2024), with operating income of $40.4 million (12.4% of revenue). Targeting >70% gross margin by end-2026.
- China revenue excluded from 2025 forecast due to macro challenges; U.S. sales accounted for 79.2% of total revenue.
- New product Lightning Bolt 12 exceeded expectations in its first full quarter, while Bolt 6X and 7 drove arterial growth.
- FDA submission for Thunderbolt completed; expect to leverage clinical data to highlight CAVT benefits vs. lytics and open surgery.

**【CFO Financial Commentary】**
- GAAP net income: $420 million; Non-GAAP EPS: $1.08 (exceeded expectations). Operating cash flow strong, with $378.8 million in cash and no debt.
- Gross margin expansion driven by favorable product mix and productivity gains. Q2 2025 gross margin expected similar to Q1 due to Ruby XL expediting costs.
- SG&A expenses: $153.5 million (47.3% of revenue), up 12.6% YoY, reflecting commercial team investments. R&D expenses: $22.1 million (6.8% of revenue), down 8.8% YoY due to immersive business wind-down.
- Adjusted EBITDA: $59.6 million (18.4% of revenue), up 64% YoY.

**【Strategy & Guidance】**
- 2025 guidance: Total revenue growth 12-14% YoY; U.S. thrombectomy growth raised to 20-21% YoY. Maintain focus on profitable growth and margin expansion.
- Ruby XL (larger peripheral coil) launched Q2/Q3 2025 to address high demand for larger vessel embolization.
- Costa Rica manufacturing expansion (scheduled to come online 2027) provides flexibility for international supply chain optimization.

**【Q&A Highlights】**
- **Stroke vs. Peripheral Growth**: Stroke business outperformed market with new RED 72 catheter adoption; arterial growth driven by Bolt 6X/7 conversions from open surgery.
- **Salesforce Disruption**: Penumbra's product superiority (CAVT technology) driving share gains, not competitor challenges.
- **International Markets**: U.S. dominates (79.2% revenue), but CAVT adoption in EMEA/Australia shows potential for future growth.
- **Tariffs & Supply Chain**: 100% U.S.-manufactured products with 75% U.S.-sourced components; strategic onshoring underway.
- **Thunderbolt Launch**: FDA review ongoing; focus on procedure time, first-pass success, and clot extraction speed vs. competitors.


Penumbra (PEN)-23 Apr 25-2025 Q1 Earnings call transcript

- **Revenue Growth**: Q4 2024 revenue up 12.9% YoY to $321.3 million, with U.S. thrombectomy sales surging 27.3%. Full-year revenue reached $1.2 billion (+13.4%).
- **Profitability Expansion**: Q4 gross margin 67.4% (vs. 65.7% YoY), targeting >70% by end-2026. Operating margin to expand to 13-14% in 2025.
- **Key Drivers**: VTE franchise grew 41% YoY, neurovascular stroke business up 20%, and new products like Lightning Bolt 12 driving adoption.
- **China Headwinds**: 2024 China revenue down $39.5 million, but 2025 impact limited to first half with de minimis headwinds by year-end.
- **Thunderbolt Outlook**: THUNDER trial completed; potential 2025 launch dependent on FDA timeline, with data presentation at major conferences.


**【CEO Summary Section】**
- **Revenue Growth**: Q4 2024 revenue was $321.3 million (adjusted), up 12.9% YoY, with U.S. thrombectomy sales growing 27.3% to $180.6 million. Full-year revenue reached $1.2 billion, a 13.4% increase. U.S. thrombectomy revenue rose 26.8% to $646.7 million.
- **Product Performance**: VTE franchise grew 41% YoY, driven by Lightning & Flash 2.0. Neurovascular stroke business grew nearly 20% YoY, with market-leading aspiration portfolio. New products like Lightning Bolt 12 and Flash 2.0 showed strong adoption.
- **Profitability**: Q4 gross margin expanded to 67.4% (vs. 65.7% YoY), operating income rose 200 bps to 15.1% of revenue. Targeting >70% gross margin by end-2026 and operating margin expansion outpacing gross margin.
- **Market Access**: Initiatives highlight CAVT's clinical and economic benefits, with data showing reduced complications and hospital cost savings. 2025 plans include additional clinical data presentations for DVT and arterial patients.

**【CFO Financial Commentary】**
- **Q4 2024 Results**: Non-GAAP revenue $321.3 million (+12.9% YoY). U.S. revenue grew 21.7%, driven by thrombectomy (+27.3%). International revenue declined 9.4% due to China (-$15.4 million). Gross margin 67.4% (vs. 65.7% YoY), operating income $48.6 million (+29.7% YoY). Adjusted EBITDA $63.7 million (+19.3% YoY).
- **Full-Year 2024**: Revenue $1.2 billion (+13.4% YoY). Thrombectomy revenue $818.1 million (+20.8% YoY). Gross margin 63.4% (including one-time $33.4 million Immersive Healthcare write-off). Operating income $106.6 million (+5.2% YoY). Target 2025 gross margin >67% and operating margin 13-14%.
- **Cash Flow**: Ended Q4 with $340.1 million in cash, up $49.1 million sequentially. Positive operating cash flow trends expected to continue.

**【Q&A Key Highlights】**
- **2025 Guidance**: Total revenue $1.34-1.36 billion (+12-14% YoY). U.S. thrombectomy growth 19-20%. Gross margin >67%, operating margin 13-14%. China headwinds (~$15 million in Q1) expected to fade by end-2025.
- **Thunderbolt Update**: THUNDER trial completed in Dec 2024. No FDA submission yet. Data presentation and potential launch in 2025 dependent on regulatory timeline.
- **Competitive Dynamics**: Market access initiatives and CAVT's clinical superiority driving share gains. No pricing impact; growth driven by volume and new product adoption.
- **R&D Spend**: $20 million in Q4 (6.2% of revenue), reflecting efficient innovation. 9 new products launched in 2024, with continued focus on CAVT expansion.


Actual												0.04	-0.34	-0.24	0.1	0.32	0.25	0.24	-0.66	-0.01	0.01	0.01	0.16	0.23	0.43	0.67	0.76	0.41	0.64	0.85	0.97	0.83	0.86	0.97
Forecast												0.132	-0.433	-0.0971	0.0865	0.09	0.1645	0.1618	0.1766	0.0402	-0.0313	-0.0038	0.1463	0.109	0.2796	0.4543	0.6988	0.3862	0.5557	0.687	0.8962	0.6669	0.8248	0.9287
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-69.70%	+21.48%	-147.17%	+15.61%	+255.56%	+51.98%	+48.33%	-473.73%	-124.88%	+131.95%	+363.16%	+9.36%	+111.01%	+53.79%	+47.48%	+8.76%	+6.16%	+15.17%	+23.73%	+8.23%	+24.46%	+4.27%	+4.45%

PEN

PEN fundamentals

PEN Q3 2025 Earnings

Earnings Call

You can ask Aime

PEN

PEN fundamentals

PEN Q3 2025 Earnings

Earnings Call

PEN Earnings Call Summary for Q3/20254:30 PM on Nov 5, 2025

PEN Earnings Call Summary for Q2/20254:30 PM on Jul 29, 2025

PEN Earnings Call Summary for Q1/20254:30 PM on Apr 23, 2025

PEN Earnings Call Summary for Q4/20244:30 PM on Feb 18, 2025

PEN Earnings Call Summary for Q3/20244:30 PM on Oct 30, 2024

You can ask Aime